» Articles » PMID: 16100168

Hypoxia-inducible Factor 1alpha Polymorphism and Coronary Collaterals in Patients with Ischemic Heart Disease

Overview
Journal Chest
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2005 Aug 16
PMID 16100168
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Study Objectives: Marked variability exists in coronary artery collaterals in patients with ischemic heart disease. Although multiple factors are thought to play a role in collateral development, the contribution of genetic factors is largely unknown. Hypoxia inducible factor 1 (HIF-1), a transcriptional activator that functions as a master regulator of oxygen homeostasis, is one possible genetic factor that could play an important role in modulating collateral development.

Design, Setting, And Participants: Collateral vessels were determined in 100 patients with > or = 70% narrowing of at least one coronary artery without acute myocardial infarction or prior revascularization. DNA was genotyped for the presence of a single nucleotide (C to T) polymorphism that changes residue 582 of HIF-1alpha from proline to serine.

Measurements And Results: The frequency of the T allele was significantly higher among patients without collaterals compared to patients with collaterals (0.188 vs 0.037, p < 0.001). In multivariate analyses, two variables affecting collateral formation were detected: two- or three-vessel coronary artery disease was a significant positive predictor (odds ratio [OR], 4.17; 95% confidence interval [CI], 1.61 to 10.8; p = 0.001), whereas the presence of HIF-1alpha genotype CT or TT was a negative predictor (OR, 0.19; 95% CI, 0.04 to 0.84; p = 0.03).

Conclusions: These data suggest that variations in HIF-1alpha genotype may influence development of coronary artery collaterals in patients with significant coronary artery disease.

Citing Articles

Detection of obstructive sleep apnea in young patients suffering from coronary artery disease by performing portable polysomnography studies.

Singh P, Chopra M, Vardhan V Med J Armed Forces India. 2022; 78(4):394-399.

PMID: 36267506 PMC: 9577263. DOI: 10.1016/j.mjafi.2020.06.005.


Fabrication of Tβ4-Exosome-releasing artificial stem cells for myocardial infarction therapy by improving coronary collateralization.

Chen P, Ning X, Li W, Pan Y, Wang L, Li H Bioact Mater. 2022; 14:416-429.

PMID: 35386821 PMC: 8964820. DOI: 10.1016/j.bioactmat.2022.01.029.


HIF in the heart: development, metabolism, ischemia, and atherosclerosis.

Kekupaa Knutson A, Williams A, Boisvert W, Shohet R J Clin Invest. 2021; 131(17).

PMID: 34623330 PMC: 8409592. DOI: 10.1172/JCI137557.


Hypoxia Inducible Factors as Central Players in the Pathogenesis and Pathophysiology of Cardiovascular Diseases.

Lucero Garcia Rojas E, Villanueva C, Bond R Front Cardiovasc Med. 2021; 8:709509.

PMID: 34447792 PMC: 8382733. DOI: 10.3389/fcvm.2021.709509.


Is Biochemical Follow Up Possible in Peripheral Arterial Disease Treatment: Hypoxia Inducible Factor-1 Alpha?.

Yucel C, Gursoy M, Ketenciler S, Tenekecigil A, Kiziltan F, Kayalar N Vasc Specialist Int. 2021; 37:29.

PMID: 34429387 PMC: 8385279. DOI: 10.5758/vsi.210011.